Jens Tidemandsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jens Tidemandsen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Kasper Aanæs
Copenhagen University Hospital, Rigshospitalet
5 shared publicationsMorten Hostrup
University of Copenhagen
5 shared publicationsVibeke Backer
Copenhagen University Hospital
5 shared publications- Anne-Sophie Homøe
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology Copenhagen University Hospital Copenhagen Denmark
4 shared publications - Howraman Meteran
Department of Respiratory Medicine Copenhagen University Hospital—Hvidovre Hvidovre Denmark
4 shared publications - Marie Høxbro
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology Copenhagen University Hospital Copenhagen Denmark
4 shared publications
Latest Publications
- 20 August 2026
- Published by SAGE Publications in American Journal of Rhinology & Allergy
AI-derived Histopathological Signatures Are Associated With Response to Mepolizumab in Chronic Rhinosinusitis With Nasal Polyps
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease with variable response to biologic therapy. Tissue-based predictors of treatment response are limited, and conventional eosinophil-focused histopathology has shown inconsistent predictive value. Objective: To assess whether artificial intelligence (AI)-derived baseline histopathology of nasal polyps contains information associated with clinical response to mepolizumab in CRSwNP. Methods: This hypothesis-generating substudy included patients with severe CRSwNP enrolled in a randomized controlled trial. Baseline biopsies were analysed using an AI-driven spatial histopathology pipeline extracting 84 morphological features per cell. Features were evaluated in eosinophil-only, noneosinophil, and all-cell configurations. Treatment response at 6 and 12 months was defined using EUFOREA criteria. Linear discriminant analysis and partial least squares regression were applied. Results: Fifty-eight patients were included. At 12 months, the eosinophil-only model showed limited discrimination (AUC ≈ 0.43), the noneosinophil model moderate discrimination (AUC ≈ 0.62), and the all-cell model the highest performance (AUC ≈ 0.75). At 6 months, all models showed limited discrimination (AUC ≈ 0.49). For continuous outcomes, noneosinophil models explained the greatest variance (R 2 up to ≈ 0.34). Conclusion: AI-derived baseline histopathology contains information associated with clinical response to mepolizumab in CRSwNP. Models incorporating the broader tissue microenvironment outperformed eosinophil-focused approaches, supporting the potential of computational pathology for pretreatment stratification of biologic therapy in CRSwNP.
- 20 August 2026
- Published by SAGE Publications in American Journal of Rhinology & Allergy
AI-derived Histopathological Signatures Are Associated With Response to Mepolizumab in Chronic Rhinosinusitis With Nasal Polyps
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease with variable response to biologic therapy. Tissue-based predictors of treatment response are limited, and conventional eosinophil-focused histopathology has shown inconsistent predictive value. Objective: To assess whether artificial intelligence (AI)-derived baseline histopathology of nasal polyps contains information associated with clinical response to mepolizumab in CRSwNP. Methods: This hypothesis-generating substudy included patients with severe CRSwNP enrolled in a randomized controlled trial. Baseline biopsies were analysed using an AI-driven spatial histopathology pipeline extracting 84 morphological features per cell. Features were evaluated in eosinophil-only, noneosinophil, and all-cell configurations. Treatment response at 6 and 12 months was defined using EUFOREA criteria. Linear discriminant analysis and partial least squares regression were applied. Results: Fifty-eight patients were included. At 12 months, the eosinophil-only model showed limited discrimination (AUC ≈ 0.43), the noneosinophil model moderate discrimination (AUC ≈ 0.62), and the all-cell model the highest performance (AUC ≈ 0.75). At 6 months, all models showed limited discrimination (AUC ≈ 0.49). For continuous outcomes, noneosinophil models explained the greatest variance (R 2 up to ≈ 0.34). Conclusion: AI-derived baseline histopathology contains information associated with clinical response to mepolizumab in CRSwNP. Models incorporating the broader tissue microenvironment outperformed eosinophil-focused approaches, supporting the potential of computational pathology for pretreatment stratification of biologic therapy in CRSwNP.
- Open Access
- 9 July 2026
- Published by Taylor & Francis in European Clinical Respiratory Journal
- Vol. 13 (1) , 2700828
Improved VO 2 max following anti-IL-5 therapy in severe eosinophilic CRSwNP: exploratory associations with cardiac inflammatory biomarkers
Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma frequently coexist [1], driven by type 2 inflammation involving eosinophils, interleukin-5 (IL-5), and systemic immune activation [2,3]....
- 9 July 2026
- Published by Taylor & Francis in European Clinical Respiratory Journal
- Vol. 13 (1) , 2700828
Open AccessImproved VO 2 max following anti-IL-5 therapy in severe eosinophilic CRSwNP: exploratory associations with cardiac inflammatory biomarkers
Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma frequently coexist [1], driven by type 2 inflammation involving eosinophils, interleukin-5 (IL-5), and systemic immune activation [2,3]....
- Open Access
- 13 April 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (8) , 914-916
Functional Endoscopic Sinus Surgery in Adults With CRSwNP Treated With Mepolizumab: Airway Physiology Outcomes From a Randomised Controlled Trial
Summary: Airway hyperresponsiveness improved after mepolizumab, particularly for indirect bronchial challenge. Analyses were exploratory and not pre‐specified in the randomised trial protocol.
- 13 April 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (8) , 914-916
Open AccessFunctional Endoscopic Sinus Surgery in Adults With CRSwNP Treated With Mepolizumab: Airway Physiology Outcomes From a Randomised Controlled Trial
Summary: Airway hyperresponsiveness improved after mepolizumab, particularly for indirect bronchial challenge. Analyses were exploratory and not pre‐specified in the randomised trial protocol.
- 3 April 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (5) , 530-531
Response to the Letter to the Editor by Pirola and Hopkins Regarding “The Global Airways in Practice: Long‐Term Effects of Mepolizumab with or without FESS on Type 2 Inflammation in Patients with CRSwNP”
- 3 April 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (5) , 530-531
Response to the Letter to the Editor by Pirola and Hopkins Regarding “The Global Airways in Practice: Long‐Term Effects of Mepolizumab with or without FESS on Type 2 Inflammation in Patients with CRSwNP”
- Open Access
- 27 March 2026
- Published by Taylor & Francis in Journal of Asthma
- Vol. 63 (8) , 1-9
Lower airway dysfunction in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): associations with asthma, ACQ5, and inflammatory markers
CRSwNP is typically a type 2 inflammatory condition of the upper airways often associated with asthma. However, emerging evidence suggests that lower airway dysfunction may also occur in CRSwNP patients without a formal asthma diagnosis. This study aimed to explore the associations between lower airway symptoms (ACQ5), lung function, airway hyperresponsiveness (AHR), and inflammatory markers in patients with CRSwNP. In this cross-sectional study, 72 patients with CRSwNP were systematically evaluated using spirometry, impulse oscillometry (IOS), methacholine and mannitol challenge tests, fractional exhaled nitric oxide (FeNO), blood and polyp eosinophil counts, and symptom scores (SNOT-22, ACQ5). Associations between ACQ5 scores and lower airway parameters were assessed using correlation and multivariable regression analyses, adjusting for asthma diagnosis and markers of type 2 inflammation. Patients with higher ACQ5 scores (>1.5) demonstrated significantly lower FEV1% predicted, FEV1/FVC, and MFEF75-25, and higher small airway resistance and AHR (p < 0.01 for all). These associations remained significant after adjustment for asthma status, FeNO, blood eosinophils, and polyp eosinophils. Inflammatory markers showed weak or no significant associations with lung function, suggesting that ACQ5 captures aspects of lower airway dysfunction in patients with CRSwNP not explained solely by type 2 inflammation. Higher ACQ5 scores in CRSwNP patients, even in the absence of asthma, are independently associated with impaired lung function, small airway dysfunction, and increased AHR. These findings support the global airway concept and highlight the potential value of ACQ5 in identifying subclinical lower airway involvement in CRSwNP.
- 27 March 2026
- Published by Taylor & Francis in Journal of Asthma
- Vol. 63 (8) , 1-9
Open AccessLower airway dysfunction in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): associations with asthma, ACQ5, and inflammatory markers
CRSwNP is typically a type 2 inflammatory condition of the upper airways often associated with asthma. However, emerging evidence suggests that lower airway dysfunction may also occur in CRSwNP patients without a formal asthma diagnosis. This study aimed to explore the associations between lower airway symptoms (ACQ5), lung function, airway hyperresponsiveness (AHR), and inflammatory markers in patients with CRSwNP. In this cross-sectional study, 72 patients with CRSwNP were systematically evaluated using spirometry, impulse oscillometry (IOS), methacholine and mannitol challenge tests, fractional exhaled nitric oxide (FeNO), blood and polyp eosinophil counts, and symptom scores (SNOT-22, ACQ5). Associations between ACQ5 scores and lower airway parameters were assessed using correlation and multivariable regression analyses, adjusting for asthma diagnosis and markers of type 2 inflammation. Patients with higher ACQ5 scores (>1.5) demonstrated significantly lower FEV1% predicted, FEV1/FVC, and MFEF75-25, and higher small airway resistance and AHR (p < 0.01 for all). These associations remained significant after adjustment for asthma status, FeNO, blood eosinophils, and polyp eosinophils. Inflammatory markers showed weak or no significant associations with lung function, suggesting that ACQ5 captures aspects of lower airway dysfunction in patients with CRSwNP not explained solely by type 2 inflammation. Higher ACQ5 scores in CRSwNP patients, even in the absence of asthma, are independently associated with impaired lung function, small airway dysfunction, and increased AHR. These findings support the global airway concept and highlight the potential value of ACQ5 in identifying subclinical lower airway involvement in CRSwNP.
- Open Access
- 29 December 2025
- Published by Taylor & Francis in European Clinical Respiratory Journal
- Vol. 13 (1)
Mepolizumab treatment is associated with physical activity and cardiorespiratory fitness irrespective of endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps: a randomised controlled trial
Cardiorespiratory fitness is a strong predictor of life expectancy and all-cause mortality. Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) often experience reduced physical activity levels due to nasal obstruction and high disease burden To evaluate whether mepolizumab, with or without sinus surgery, is associated with changes in habitual physical activity and cardiorespiratory fitness. In this randomized trial (NCT05598814), 58 adults with severe CRSwNP were randomized (1:1) to receive either sinus surgery with mepolizumab (FESS) or mepolizumab alone (nonFESS). Inclusion criteria included CRS symptoms, nasal polyp score (NPS) ≥4, SNOT-22 score > 35, signs of type 2 inflammation, and prior functional endoscopic sinus surgery (FESS). Patients received 100 mg of mepolizumab every four weeks for six months. No exercise was prescribed, though participants were aware activity was being tracked. Physical activity (step count), fitness score (VO2max/kg), and disease burden were assessed at baseline and follow-up. The FESS (n = 29) and nonFESS (n = 29) groups had a mean age of 52 (14) years, with 74% male participants. Both groups demonstrated significant increases in VO2max (FESS: +1.95 ml/min/kg, +6%, p < 0.001; nonFESS: +1.50 ml/min/kg, +5%, p < 0.001) and daily step count (FESS: +1117 steps, p < 0.001; nonFESS: +1087 steps, p = 0.001). SNOT-22 scores decreased significantly in both groups, with greater improvement in the FESS group (−42 vs. −32 points, p = 0.040). Mepolizumab was associated with improvement in physical activity, fitness, and quality of life. FESS provided additional quality-of-life benefits but did not further enhance fitness outcomes.
- 29 December 2025
- Published by Taylor & Francis in European Clinical Respiratory Journal
- Vol. 13 (1)
Open AccessMepolizumab treatment is associated with physical activity and cardiorespiratory fitness irrespective of endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps: a randomised controlled trial
Cardiorespiratory fitness is a strong predictor of life expectancy and all-cause mortality. Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) often experience reduced physical activity levels due to nasal obstruction and high disease burden To evaluate whether mepolizumab, with or without sinus surgery, is associated with changes in habitual physical activity and cardiorespiratory fitness. In this randomized trial (NCT05598814), 58 adults with severe CRSwNP were randomized (1:1) to receive either sinus surgery with mepolizumab (FESS) or mepolizumab alone (nonFESS). Inclusion criteria included CRS symptoms, nasal polyp score (NPS) ≥4, SNOT-22 score > 35, signs of type 2 inflammation, and prior functional endoscopic sinus surgery (FESS). Patients received 100 mg of mepolizumab every four weeks for six months. No exercise was prescribed, though participants were aware activity was being tracked. Physical activity (step count), fitness score (VO2max/kg), and disease burden were assessed at baseline and follow-up. The FESS (n = 29) and nonFESS (n = 29) groups had a mean age of 52 (14) years, with 74% male participants. Both groups demonstrated significant increases in VO2max (FESS: +1.95 ml/min/kg, +6%, p < 0.001; nonFESS: +1.50 ml/min/kg, +5%, p < 0.001) and daily step count (FESS: +1117 steps, p < 0.001; nonFESS: +1087 steps, p = 0.001). SNOT-22 scores decreased significantly in both groups, with greater improvement in the FESS group (−42 vs. −32 points, p = 0.040). Mepolizumab was associated with improvement in physical activity, fitness, and quality of life. FESS provided additional quality-of-life benefits but did not further enhance fitness outcomes.
- Open Access
- 15 December 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (4) , 369-379
The Global Airways in Practice: Long‐term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery (FESS) primarily addresses sinonasal disease and can improve asthma control. The combined effect on airway outcomes remains unclear. This study evaluated the global airway hypothesis with objective measures and targeted therapies. Objective: To investigate the impact of mepolizumab, with or without FESS, on airway inflammation, lung function, and symptom burden in severe CRSwNP with or without asthma. Methods: In this RCT, 58 patients received either mepolizumab alone or combined with FESS. Inflammation and symptom outcomes were analyzed in blood, nose, and bronchi at baseline, six, and 12 months. Patients were stratified by baseline inflammatory subgroup. Results: Both groups showed improvements in FEV1% (MepoFESS: +3.4%, p = 0.010; Mepo Only: +3.5%, p = 0.015), FVC% (MepoFESS: +3.7%, p < 0.001; Mepo Only: +2.9%, p = 0.009), inflammation markers (FeNO, blood eosinophils, nasal polyp eosinophils), and all patient‐reported outcomes. MepoFESS produced greater gains in nasal polyp score, nasal congestion, and overall symptom burden. Lung function and systemic inflammation improved similarly in both groups. Conclusions: Mepolizumab improves upper and lower airway outcomes in CRSwNP. FESS adds localized benefits in sinonasal symptom control without further impact on lower airway inflammation. Findings support a comprehensive approach targeting systemic and local type 2 inflammation in global airway disease.
- 15 December 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (4) , 369-379
Open AccessThe Global Airways in Practice: Long‐term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery (FESS) primarily addresses sinonasal disease and can improve asthma control. The combined effect on airway outcomes remains unclear. This study evaluated the global airway hypothesis with objective measures and targeted therapies. Objective: To investigate the impact of mepolizumab, with or without FESS, on airway inflammation, lung function, and symptom burden in severe CRSwNP with or without asthma. Methods: In this RCT, 58 patients received either mepolizumab alone or combined with FESS. Inflammation and symptom outcomes were analyzed in blood, nose, and bronchi at baseline, six, and 12 months. Patients were stratified by baseline inflammatory subgroup. Results: Both groups showed improvements in FEV1% (MepoFESS: +3.4%, p = 0.010; Mepo Only: +3.5%, p = 0.015), FVC% (MepoFESS: +3.7%, p < 0.001; Mepo Only: +2.9%, p = 0.009), inflammation markers (FeNO, blood eosinophils, nasal polyp eosinophils), and all patient‐reported outcomes. MepoFESS produced greater gains in nasal polyp score, nasal congestion, and overall symptom burden. Lung function and systemic inflammation improved similarly in both groups. Conclusions: Mepolizumab improves upper and lower airway outcomes in CRSwNP. FESS adds localized benefits in sinonasal symptom control without further impact on lower airway inflammation. Findings support a comprehensive approach targeting systemic and local type 2 inflammation in global airway disease.
- RetractedOpen Access
- 20 November 2025
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 25 (1) , 54
RETRACTED ARTICLE: Restoring the Sense of Smell: A Systematic Review and Meta-Analysis of Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyps
Purpose of Review Smell loss is among the most debilitating symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP). We aimed to synthesize current evidence on the smell-restoring efficacy of biologics, focusing on outcomes measured by psychophysical tests. Recent Findings Biologics mark a paradigm shift in the management of refractory CRSwNP, offering targeted, effective and safe treatment options. However, their relative impact on psychophysical smell outcomes remains uncertain. With several biologics now approved and real-world evidence emerging, a comprehensive evaluation is needed. Summary This is a systematic review and meta-analysis of 8 RCTs (n = 2,024) and an additional review of 20 cohorts (n = 1,685). Among RCTs, biologic treatment produced a moderate to large pooled improvement in psychophysical smell scores (standardized mean difference, [SMD] = 0.72 (95% CI 0.32–1.13), p = 0.0004). The effect differed between drugs (χ² = 23.95, p < 0.0002). Dupilumab showed the largest improvements across four RCTs (SMD = 1.16, 95% CI = 0.35–1.97). In single RCTs, benralizumab showed large effect (1.03, 0.55–1.51), tezepelumab (0.56, 0.46–0.67), telikibart (0.35, 0.11–0.59), and omalizumab (0.27, 0.15–0.40) yielded modest but significant improvements. Mepolizumab showed no effect (0.1330 (95% CI −0.2490–0.5150). Blood-eosinophil level correlated with treatment response (p < 0.001). The cohort studies supported the findings (SMD = 1.20, 95% CI = 0.99–1.42), though most data were derived from studies of dupilumab. Overall, biologics substantially improve psychophysically measured olfactory function in CRSwNP. Future head-to-head trials are warranted to delineate comparative efficacy of smell recovery.
- 20 November 2025
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 25 (1) , 54
RetractedOpen AccessRETRACTED ARTICLE: Restoring the Sense of Smell: A Systematic Review and Meta-Analysis of Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyps
Purpose of Review Smell loss is among the most debilitating symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP). We aimed to synthesize current evidence on the smell-restoring efficacy of biologics, focusing on outcomes measured by psychophysical tests. Recent Findings Biologics mark a paradigm shift in the management of refractory CRSwNP, offering targeted, effective and safe treatment options. However, their relative impact on psychophysical smell outcomes remains uncertain. With several biologics now approved and real-world evidence emerging, a comprehensive evaluation is needed. Summary This is a systematic review and meta-analysis of 8 RCTs (n = 2,024) and an additional review of 20 cohorts (n = 1,685). Among RCTs, biologic treatment produced a moderate to large pooled improvement in psychophysical smell scores (standardized mean difference, [SMD] = 0.72 (95% CI 0.32–1.13), p = 0.0004). The effect differed between drugs (χ² = 23.95, p < 0.0002). Dupilumab showed the largest improvements across four RCTs (SMD = 1.16, 95% CI = 0.35–1.97). In single RCTs, benralizumab showed large effect (1.03, 0.55–1.51), tezepelumab (0.56, 0.46–0.67), telikibart (0.35, 0.11–0.59), and omalizumab (0.27, 0.15–0.40) yielded modest but significant improvements. Mepolizumab showed no effect (0.1330 (95% CI −0.2490–0.5150). Blood-eosinophil level correlated with treatment response (p < 0.001). The cohort studies supported the findings (SMD = 1.20, 95% CI = 0.99–1.42), though most data were derived from studies of dupilumab. Overall, biologics substantially improve psychophysically measured olfactory function in CRSwNP. Future head-to-head trials are warranted to delineate comparative efficacy of smell recovery.